Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter

Rheaclare Fraser-Spears, Anwen M. Krause-Heuer, Mohamed Basiouny, Felix P. Mayer, Retrouvailles Manishimwe, Naomi A. Wyatt, Jeremy C. Dobrowolski, Maxine P. Roberts, Ivan Greguric, Naresh Kumar, Wouter Koek, Harald H. Sitte, Paul D. Callaghan, Benjamin H. Fraser, Lynette C Daws

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Growing evidence supports involvement of low-affinity/high-capacity organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) in regulating clearance of monoamines. Currently decynium-22 (D22) is the best pharmacological tool to study these transporters, however it does not readily discriminate among them, underscoring a need to develop compounds with greater selectivity for each of these transporters. We developed seven D22 analogs, and previously reported that some have lower affinity for α1-adrenoceptors than D22 and showed antidepressant-like activity in mice. Here, we extend these findings to determine the affinity of these analogs for OCT2, OCT3 and PMAT, as well as serotonin, norepinephrine and dopamine transporters (SERT, NET and DAT) using a combination of uptake competition with [3H]methyl-4-phenylpyridinium acetate in overexpressed HEK cells and [3H]citalopram, [3H]nisoxetine and [3H]WIN 35428 displacement binding in mouse hippocampal and striatal preparations. Like D22, all analogs showed greater binding affinities for OCT3 than OCT2 and PMAT. However, unlike D22, some analogs also showed modest affinity for SERT and DAT. Dual OCT3/SERT and/or OCT3/DAT actions of certain analogs may help explain their ability to produce antidepressant-like effects in mice and help account for our previous findings that D22 lacks antidepressant-like effects unless SERT function is either genetically or pharmacologically compromised. Though these analogs are not superior than D22 in discriminating among OCTs/PMAT, our findings point to development of compounds with combined ability to inhibit both low-affinity/high-capacity transporters, such as OCT3, and high-affinity/low-capacity transporters, such as SERT, as therapeutics with potentially improved efficacy for treatment of psychiatric disorders.

Original languageEnglish (US)
Pages (from-to)351-364
Number of pages14
JournalEuropean Journal of Pharmacology
Volume842
DOIs
StatePublished - Jan 5 2019

Fingerprint

Membrane Transport Proteins
Cations
Cell Membrane
Antidepressive Agents
nisoxetine
Norepinephrine Plasma Membrane Transport Proteins
Corpus Striatum
Serotonin Plasma Membrane Transport Proteins
Citalopram
Dopamine Plasma Membrane Transport Proteins
pseudoisocyanine
Adrenergic Receptors
Psychiatry
Acetates
Pharmacology

Keywords

  • Antidepressants
  • Decynium-22
  • Monoamine uptake
  • Organic cation transporters
  • Plasma membrane monoamine transporter
  • Transporter inhibition

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter. / Fraser-Spears, Rheaclare; Krause-Heuer, Anwen M.; Basiouny, Mohamed; Mayer, Felix P.; Manishimwe, Retrouvailles; Wyatt, Naomi A.; Dobrowolski, Jeremy C.; Roberts, Maxine P.; Greguric, Ivan; Kumar, Naresh; Koek, Wouter; Sitte, Harald H.; Callaghan, Paul D.; Fraser, Benjamin H.; Daws, Lynette C.

In: European Journal of Pharmacology, Vol. 842, 05.01.2019, p. 351-364.

Research output: Contribution to journalArticle

Fraser-Spears, R, Krause-Heuer, AM, Basiouny, M, Mayer, FP, Manishimwe, R, Wyatt, NA, Dobrowolski, JC, Roberts, MP, Greguric, I, Kumar, N, Koek, W, Sitte, HH, Callaghan, PD, Fraser, BH & Daws, LC 2019, 'Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter', European Journal of Pharmacology, vol. 842, pp. 351-364. https://doi.org/10.1016/j.ejphar.2018.10.028
Fraser-Spears, Rheaclare ; Krause-Heuer, Anwen M. ; Basiouny, Mohamed ; Mayer, Felix P. ; Manishimwe, Retrouvailles ; Wyatt, Naomi A. ; Dobrowolski, Jeremy C. ; Roberts, Maxine P. ; Greguric, Ivan ; Kumar, Naresh ; Koek, Wouter ; Sitte, Harald H. ; Callaghan, Paul D. ; Fraser, Benjamin H. ; Daws, Lynette C. / Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter. In: European Journal of Pharmacology. 2019 ; Vol. 842. pp. 351-364.
@article{1a4e6c93bd084d48acab23de47093ae2,
title = "Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter",
abstract = "Growing evidence supports involvement of low-affinity/high-capacity organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) in regulating clearance of monoamines. Currently decynium-22 (D22) is the best pharmacological tool to study these transporters, however it does not readily discriminate among them, underscoring a need to develop compounds with greater selectivity for each of these transporters. We developed seven D22 analogs, and previously reported that some have lower affinity for α1-adrenoceptors than D22 and showed antidepressant-like activity in mice. Here, we extend these findings to determine the affinity of these analogs for OCT2, OCT3 and PMAT, as well as serotonin, norepinephrine and dopamine transporters (SERT, NET and DAT) using a combination of uptake competition with [3H]methyl-4-phenylpyridinium acetate in overexpressed HEK cells and [3H]citalopram, [3H]nisoxetine and [3H]WIN 35428 displacement binding in mouse hippocampal and striatal preparations. Like D22, all analogs showed greater binding affinities for OCT3 than OCT2 and PMAT. However, unlike D22, some analogs also showed modest affinity for SERT and DAT. Dual OCT3/SERT and/or OCT3/DAT actions of certain analogs may help explain their ability to produce antidepressant-like effects in mice and help account for our previous findings that D22 lacks antidepressant-like effects unless SERT function is either genetically or pharmacologically compromised. Though these analogs are not superior than D22 in discriminating among OCTs/PMAT, our findings point to development of compounds with combined ability to inhibit both low-affinity/high-capacity transporters, such as OCT3, and high-affinity/low-capacity transporters, such as SERT, as therapeutics with potentially improved efficacy for treatment of psychiatric disorders.",
keywords = "Antidepressants, Decynium-22, Monoamine uptake, Organic cation transporters, Plasma membrane monoamine transporter, Transporter inhibition",
author = "Rheaclare Fraser-Spears and Krause-Heuer, {Anwen M.} and Mohamed Basiouny and Mayer, {Felix P.} and Retrouvailles Manishimwe and Wyatt, {Naomi A.} and Dobrowolski, {Jeremy C.} and Roberts, {Maxine P.} and Ivan Greguric and Naresh Kumar and Wouter Koek and Sitte, {Harald H.} and Callaghan, {Paul D.} and Fraser, {Benjamin H.} and Daws, {Lynette C}",
year = "2019",
month = "1",
day = "5",
doi = "10.1016/j.ejphar.2018.10.028",
language = "English (US)",
volume = "842",
pages = "351--364",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter

AU - Fraser-Spears, Rheaclare

AU - Krause-Heuer, Anwen M.

AU - Basiouny, Mohamed

AU - Mayer, Felix P.

AU - Manishimwe, Retrouvailles

AU - Wyatt, Naomi A.

AU - Dobrowolski, Jeremy C.

AU - Roberts, Maxine P.

AU - Greguric, Ivan

AU - Kumar, Naresh

AU - Koek, Wouter

AU - Sitte, Harald H.

AU - Callaghan, Paul D.

AU - Fraser, Benjamin H.

AU - Daws, Lynette C

PY - 2019/1/5

Y1 - 2019/1/5

N2 - Growing evidence supports involvement of low-affinity/high-capacity organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) in regulating clearance of monoamines. Currently decynium-22 (D22) is the best pharmacological tool to study these transporters, however it does not readily discriminate among them, underscoring a need to develop compounds with greater selectivity for each of these transporters. We developed seven D22 analogs, and previously reported that some have lower affinity for α1-adrenoceptors than D22 and showed antidepressant-like activity in mice. Here, we extend these findings to determine the affinity of these analogs for OCT2, OCT3 and PMAT, as well as serotonin, norepinephrine and dopamine transporters (SERT, NET and DAT) using a combination of uptake competition with [3H]methyl-4-phenylpyridinium acetate in overexpressed HEK cells and [3H]citalopram, [3H]nisoxetine and [3H]WIN 35428 displacement binding in mouse hippocampal and striatal preparations. Like D22, all analogs showed greater binding affinities for OCT3 than OCT2 and PMAT. However, unlike D22, some analogs also showed modest affinity for SERT and DAT. Dual OCT3/SERT and/or OCT3/DAT actions of certain analogs may help explain their ability to produce antidepressant-like effects in mice and help account for our previous findings that D22 lacks antidepressant-like effects unless SERT function is either genetically or pharmacologically compromised. Though these analogs are not superior than D22 in discriminating among OCTs/PMAT, our findings point to development of compounds with combined ability to inhibit both low-affinity/high-capacity transporters, such as OCT3, and high-affinity/low-capacity transporters, such as SERT, as therapeutics with potentially improved efficacy for treatment of psychiatric disorders.

AB - Growing evidence supports involvement of low-affinity/high-capacity organic cation transporters (OCTs) and plasma membrane monoamine transporter (PMAT) in regulating clearance of monoamines. Currently decynium-22 (D22) is the best pharmacological tool to study these transporters, however it does not readily discriminate among them, underscoring a need to develop compounds with greater selectivity for each of these transporters. We developed seven D22 analogs, and previously reported that some have lower affinity for α1-adrenoceptors than D22 and showed antidepressant-like activity in mice. Here, we extend these findings to determine the affinity of these analogs for OCT2, OCT3 and PMAT, as well as serotonin, norepinephrine and dopamine transporters (SERT, NET and DAT) using a combination of uptake competition with [3H]methyl-4-phenylpyridinium acetate in overexpressed HEK cells and [3H]citalopram, [3H]nisoxetine and [3H]WIN 35428 displacement binding in mouse hippocampal and striatal preparations. Like D22, all analogs showed greater binding affinities for OCT3 than OCT2 and PMAT. However, unlike D22, some analogs also showed modest affinity for SERT and DAT. Dual OCT3/SERT and/or OCT3/DAT actions of certain analogs may help explain their ability to produce antidepressant-like effects in mice and help account for our previous findings that D22 lacks antidepressant-like effects unless SERT function is either genetically or pharmacologically compromised. Though these analogs are not superior than D22 in discriminating among OCTs/PMAT, our findings point to development of compounds with combined ability to inhibit both low-affinity/high-capacity transporters, such as OCT3, and high-affinity/low-capacity transporters, such as SERT, as therapeutics with potentially improved efficacy for treatment of psychiatric disorders.

KW - Antidepressants

KW - Decynium-22

KW - Monoamine uptake

KW - Organic cation transporters

KW - Plasma membrane monoamine transporter

KW - Transporter inhibition

UR - http://www.scopus.com/inward/record.url?scp=85056785826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056785826&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2018.10.028

DO - 10.1016/j.ejphar.2018.10.028

M3 - Article

VL - 842

SP - 351

EP - 364

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -